News Search Results
Apr 03, 2025, 07:00 ET Corero Network Security Secures Major 400G TechEnabler Deal, Marks Fourth Brazil Win in Four Months
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), the distributed denial of service (DDoS) protection specialists, announced a new strategic partnership with Brazil-based
More news about: Corero Network Security
Apr 03, 2025, 07:00 ET UCB presents latest research across leading neurology portfolio at American Academy of Neurology (AAN) meeting 2025
is observed.Somnolence, Sedation, and Lethargy: FINTEPLA can cause somnolence, sedation, and lethargy. Other central nervous system (CNS) depressants, including alcohol, could potentiate these effects of FINTEPLA. Prescribers should monitor patients for somnolence and sedation and should
More news about: UCB
Apr 02, 2025, 18:49 ET Robbins LLP Reminds SANA Investors with Large Losses to Contact the Firm for Information About the Securities Fraud Class Action Against Sana Biotechnology, Inc.
treatment across a broad array of therapeutic areas with unmet treatment needs, including, inter alia, oncology, diabetes, central nervous system ("CNS") disorders, and B-cell-mediated autoimmune diseases.
More news about: Robbins LLP
Apr 01, 2025, 09:30 ET Monteris Medical Announces College of Neurological Surgeons Guidelines Issued on Laser Interstitial Thermal Therapy for the Treatment of Adults with Metastatic Brain Tumors
Monteris Medical announced today that the College of Neurological Surgeons (CNS) has issued clinical guidelines supporting the use of laser interstitial thermal therapy (LITT) for adults with progressive metastatic brain tumors,
More news about: Monteris Medical
Apr 01, 2025, 07:00 ET Juniper Networks Expands Partnership with Corero Network Security to Deliver Industry-Leading DDoS Protection Across Any Network
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), the DDoS protection specialists, today announced an expansion of its partnership with Juniper Networks, enabling Juniper to sell Corero's
More news about: Corero Network Security
Apr 01, 2025, 06:18 ET Dizal Announces DZD8586 and DZD6008 Presentations at 2025 ASCO Annual Meeting
animal models. Phase I clinical trial suggests that DZD8586 exhibits favorable PK properties, good central nervous system (CNS) permeability, complete blockade of BCR signaling, and encouraging anti-tumor efficacy with good safety and tolerability in patients with B-NHL.
More news about: Dizal Pharmaceutical
Mar 31, 2025, 17:52 ET Cohen & Steers Quality Income Realty Fund, Inc. (RQI) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS) About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income,
More news about: Cohen & Steers, Inc.
Mar 31, 2025, 17:49 ET Cohen & Steers Closed-End Opportunity Fund, Inc. (FOF) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS) About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income,
More news about: Cohen & Steers, Inc.
Mar 31, 2025, 17:46 ET Cohen & Steers Infrastructure Fund, Inc. (UTF) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS) About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income,
More news about: Cohen & Steers, Inc.
Mar 31, 2025, 17:28 ET Cohen & Steers Total Return Realty Fund, Inc. (RFI) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.com/Symbol: (NYSE: CNS) About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income,
More news about: Cohen & Steers, Inc.
Mar 31, 2025, 17:21 ET Cohen & Steers REIT and Preferred and Income Fund, Inc. (RNP) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.com/Symbol: (NYSE: CNS) About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income,
More news about: Cohen & Steers, Inc.
Mar 31, 2025, 12:43 ET INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers - SANA
oncology, diabetes, central nervous system ("CNS") disorders, and B-cell-mediated autoimmune diseases. The Company's product candidates include, among others, SC291 for the treatment of, inter alia, B-cell malignancies; SC379 for the treatment of certain CNS disorders; and SG299, which is part of
More news about: Pomerantz LLP
Mar 31, 2025, 09:00 ET Mitsubishi Tanabe Pharma America to Share Latest Data on Investigational ND0612 at the 2025 International Conference on Alzheimer's and Parkinson's Diseases (AD/PD)
combination therapies and technologies. NeuroDerm is an integrated pharmaceutical and medical technology company developing central nervous system (CNS) product candidates. For additional information, please visit NeuroDerm's website at
More news about: Mitsubishi Tanabe Pharma America
Mar 31, 2025, 07:30 ET Kazia Therapeutics Announces Sale of Intellectual Property and Trademarks Rights for Cantrixil
standard approval. Other clinical trials involving paxalisib are ongoing in advanced breast cancer, brain metastases, diffuse midline gliomas, and primary CNS lymphoma, with several of these trials having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation for glioblastoma by the
More news about: Kazia Therapeutics Limited
Mar 31, 2025, 07:30 ET Transcend Therapeutics Announces Primary Endpoint Met in IMPACT-1 Phase 2 Study of TSND-201 in PTSD
5HT-2a (i.e., not hallucinogenic). Transcend is developing TSND-201 as a rapid-acting and durable treatment for PTSD and other central nervous system (CNS) indications. TSND-201 is an investigational medication. About PTSDPTSD is a mental health condition that can occur after experiencing
More news about: Transcend Therapeutics
Mar 27, 2025, 16:05 ET Cohen & Steers Closed-End Funds Declare Distributions for April, May and June 2025
https://www.cohenandsteers.com/Symbol: (NYSE: CNS) About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income,
More news about: Cohen & Steers, Inc.
Mar 26, 2025, 10:00 ET NEURIM PHARMACEUTICALS RECEIVES EUROPEAN MARKETING AUTHORIZATION FOR PEDIATRIC PROLONGED-RELEASE MELATONIN (SLENYTO®) FOR THE TREATMENT OF INSOMNIA IN CHILDREN WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
available in 45 countries around the world. Neurim has a strong and innovative product pipeline targeting central nervous system (CNS) disorders. Contact: Guy Manor, VP Commercial Operations,
More news about: Neurim Pharmaceuticals
Mar 26, 2025, 10:00 ET NEURIM PHARMACEUTICALS RECEIVES EUROPEAN MARKETING AUTHORIZATION FOR PEDIATRIC PROLONGED-RELEASE MELATONIN (SLENYTO®) FOR THE TREATMENT OF INSOMNIA IN CHILDREN WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
available in 45 countries around the world. Neurim has a strong and innovative product pipeline targeting central nervous system (CNS) disorders. Contact: Guy Manor, VP Commercial Operations,
More news about: Neurim Pharmaceuticals
Mar 26, 2025, 07:00 ET Yoda Therapeutics Announces First Patient Dosed in Phase 2 Trial of YA-101 for Multiple System Atrophy
March 26, 2025 /PRNewswire/ -- Yoda Therapeutics Inc. (YODA), an AI-driven company that focuses on Central Nervous System (CNS) drugs, today announced the dosing of the first patient in the Phase 2 trial of YA-101 for Multiple System Atrophy (MSA) in the
More news about: Yoda Therapeutics Inc.
Mar 26, 2025, 07:00 ET National Kidney Foundation Honors Clinical Nurse Specialist with Prestigious Carol Mattix Award
home dialysis and improve their quality of life and health," said Kortyna. "Working to support their health has brought me great joy. As a hospital CNS, I hope others like me continue to strive to increase the choices and improve the quality of the services offered." Kortyna's first experience
More news about: National Kidney Foundation
Mar 26, 2025, 05:00 ET NEURIM PHARMACEUTICALS RECEIVES EUROPEAN MARKETING AUTHORIZATION FOR PEDIATRIC PROLONGED-RELEASE MELATONIN (SLENYTO®) FOR THE TREATMENT OF INSOMNIA IN CHILDREN WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
commercially available in 45 countries around the world. Neurim has a strong and innovative product pipeline targeting central nervous system (CNS) disorders. Contact: Guy Manor, VP Commercial Operations,
More news about: Neurim Pharmaceuticals
Mar 25, 2025, 17:24 ET Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor, Neladalkib, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2025
for central nervous system (CNS) penetrance to improve treatment options for patients with brain metastases, and to avoid inhibition of the structurally related tropomyosin receptor kinase (TRK) family. Together, these characteristics have the potential to avoid TRK-related CNS adverse events seen with
More news about: Nuvalent, Inc.
Mar 25, 2025, 16:35 ET Lilly announces details of presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting
Presentation Title: LY4066434, an oral small molecule pan-KRAS inhibitor, demonstrates robust anti-tumor activity in KRAS-mutant models, including in the CNS Abstract Number: 4375Session Date & Time: Tuesday, April 29, 9
More news about: Eli Lilly and Company
Mar 25, 2025, 11:27 ET Belay Diagnostics Partners with GenomOncology to Support High-Performance Liquid Biopsy Test for Central Nervous System Cancer Detection
management of primary and secondary central nervous system (CNS) malignancies. Summit detects single nucleotide variants, multi-nucleotide variants, insertions and deletions, and chromosome arm level loss/gain from DNA in genes known to be associated with CNS tumors. A second novel test, Vantage™ MGMT
More news about: GenomOncology
Mar 25, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers - SANA
oncology, diabetes, central nervous system ("CNS") disorders, and B-cell-mediated autoimmune diseases. The Company's product candidates include, among others, SC291 for the treatment of, inter alia, B-cell malignancies; SC379 for the treatment of certain CNS disorders; and SG299, which is part of
More news about: Pomerantz LLP